Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22154645 | 0.84 | CA14 (0.36) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL9535145 | 0.83 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL5460363 | 0.78 | CA14 (0.53) | HDAC6HDAC1HDAC2CA14MAOA | |
| SCHEMBL31324971 | 0.77 | CA14 (0.51) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL55404 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL1274075 | 0.77 | CA14 (0.55) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL25719038 | 0.76 | MAPT (0.35) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL9537778 | 0.76 | CTSK (0.34) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL2836031 | 0.76 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL10226299 | 0.75 | CA14 (0.54) | HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7834037-B2 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | LTC4S, ALOX5, LTA4H | HDAC6 3802/4885HDAC1 2373/4885HDAC2 2076/4885 |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | HDAC6 3940/4885HDAC1 2525/4885HDAC2 3233/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | HDAC6 3940/4885HDAC1 2525/4885HDAC2 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.